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Founder mutation in Usher Syndrome Type 1 <p>Genetic characterisation of 15 French Canadian patients from different regions of the province of Quebec who were clinically diagnosed  as USH1 reveals that carriers of the c.216G&gt;A-allele haplotype belong to the early founders of both the Acadian and the Quebec popula- tion.</p>
Abstract
Background: Usher syndrome type 1 (USH1) is the leading cause of deafblindness. In most
populations, many private mutations are distributed across the five known USH1 genes. We
investigated patients from the French Canadian population of Quebec (approximately 6 million
people) that descends from about 8,500 French settlers who colonized the St Lawrence River valley
between 1608 and 1759. We hypothesized that founder mutations in USH1 genes exist in this
population.
Results: We have genetically characterized 15 patients from different regions of Quebec who
were clinically diagnosed as USH1. Of these cases, 60% carried mutations of the USH1C gene, a
genetic subtype that is rare outside the Acadian population. We have discovered a founder effect
of the c.216G>A mutation, which has previously been designated the 'Acadian allele' because it
accounts for virtually all Acadian USH1 cases. It represents 40% of disease alleles in Quebec, and a
carrier of c.216G>A was identified in the general population. Mutations in other genes, except
CDH23, are very rare.
Conclusion: Based on our findings, approximately 0.5% of congenitally deaf children in Quebec
are at risk of developing retinal degeneration due to homozygosity for c.216G>A. Although the
Acadians and French Canadians from Quebec are descended from French ancestors, they have
always been considered genetically distinct. The genetic conditions common in Quebec are
generally not found in Acadians, or they are due to different mutations. Our results, however, show
that carriers of the c.216G>A allele haplotype belonged to the early founders of both the Acadian
and the Quebec population.
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Background
Usher syndrome (USH) is an autosomal recessive condition
characterized by sensorineural hearing loss, variable vestibu-
lar dysfunction, and visual impairment due to retinitis pig-
mentosa. It is the leading cause of deafblindness, with a
general prevalence of 2 to 6.2 in 100,000 [1,2]. Three clinical
subtypes are distinguished, with type 1 (USH1; MIM 276900)
representing the most severe subtype with profound congen-
ital deafness, vestibular dysfunction, and prepubertal onset of
retinitis pigmentosa. To date, five USH1 genes have been
identified [3-10]. In a recent study on USH1 patients from the
US and the UK, 39% of patients had mutations in myosin-7A
(MYO7A/USH1B) or cadherin-23 (CDH23/USH1D), 11% had
mutations in protocadherin-15 (PCDH15/USH1F), 7% had
mutations in SANS  (USH1G), and 7% had mutations in
USH1C  (non-Acadians) [11]. These proportions are in line
with most investigations of other populations where MYO7A
is the most commonly mutated gene in USH1. However, in
the Ashkenazi Jewish population and the Acadian population
of the Southern United States, founder effects for USH1F and
for USH1C, respectively, lead to locally high incidences of
these genetic subtypes [12,13].
The current French Canadian population of Quebec of
approximately 6 million people descends from about 8,500
French settlers who colonized the St Lawrence River valley
between 1608 and 1759. The 2,600 settlers who arrived
before 1680 contributed about two-thirds of the current gene
pool [14]. We hypothesized that one or more founder muta-
tions in USH1 genes may exist in this population. In order to
investigate this, we have evaluated 15 USH1 patients (from 15
separate families) from different parts of Quebec for muta-
tions in all known USH1 genes. Several founder mutations
were identified, including an USH1C mutation that has previ-
ously been described almost exclusively in Acadians, where it
is responsible for virtually all USH1 cases. In our patients
from Quebec, this mutation accounts for 40% of disease alle-
les, a finding that will have a major impact on diagnostic and
clinical management of deaf children in Quebec. Although
Acadians and Quebecers are both French Canadian, Acadia
was founded four years prior to Quebec and in a geographi-
cally separate area now corresponding to New Brunswick and
Nova Scotia. Acadians to a great extent came from different
parts of France than do Quebecois. (the meaning of the sen-
tence has been altered by editing; what we want to say is that
Acadians came from other regions of France than Quebec
people ("Quebecois" is just an alternative expression for
"Quebecers") Consequently, the two populations are consid-
ered genetically distinct and do not share the same propensity
for genetic disorders. However, our data for the first time pro-
vide evidence for a genetic link between the population of
Quebec and the Acadians, a link that has previously been
regarded as unlikely.
Results
USH1C: novel mutations and a wide-spread founder 
mutation
Mutation screening in exons 1, 2, 3, 5 and 6 of the USH1C gene
revealed the previously reported exon 3 mutation c.216G>A
in a homozygous state in four patients (one of the two corre-
sponding families is shown in Additional data file 1b).
Another four patients with the c.216G>A mutation were
found to be compound heterozygotes, carrying different
USH1C  mutations on the second allele: c.238-239insC in
exon 3 (see Additional data file 1c), and two novel mutations,
c . 4 6 3 C > T  i n  e x o n  5  ( s e e  A d d i t i o n a l  d a t a  f i l e  1 d ) ,  a n d
c.496+1G>T in intron 5 (two patients; see Additional data file
1e). One patient was compound heterozygous for c.ins238-
239insC and a novel deletion in exon 9, c.748_759+5del (see
Additional data file 1f). All novel USH1C mutations are pre-
dicted to be truncating: c.463C>T creates an in-frame stop
codon (p.R155X), whereas both c.496+1G>T and
c.748_759+5del probably lead to aberrant splicing. In
c.496+1G>T, the transversion affects the invariant consensus
sequence of the exon 5 donor splice site. A G-to-A transition
at the same position has been reported previously in an USH1
patient [15]. In c.748_759+5del, the twelve last nucleotides of
exon 9 and five intronic nucleotides, including the donor
splice site, are deleted. In sum, USH1C mutations account for
60% of disease alleles in our French Canadian USH1 patient
cohort, with c.216G>A alone accounting for 40% (Figure 1a).
The silent mutation c.216G>A has previously been shown to
result in aberrant splicing of the USH1C gene [16]. It has been
described as a founder mutation restricted to the Acadian
population ('Acadian allele'), where it accounts for virtually
all USH1 cases [5,8,17] and is in complete linkage disequilib-
rium with the 9VNTR(t,t) allele of a 45 base-pair (bp) variable
number of tandem repeat (VNTR) polymorphism in intron 5
of the USH1C gene [17].
In our cohort, the c.216G>A mutation accounts for 40% of
disease alleles. While all other mutations identified in our
study were absent in 100 French Canadian control samples
from Quebec, c.216G>A was present in a heterozygous state
in one out of 227 healthy control individuals, suggesting a car-
rier rate of about 0.44% in the Quebec population. In order to
elucidate the c.216G>A haplotype, we analyzed genotypes of
16 intragenic single nucleotide polymorphisms (SNPs), the
intron 5 VNTR, and locus-specific microsatellite markers of
the USH1C locus. The results were consistent with a common
ancestral c.216G>A-associated haplotype in our eight
patients from Quebec, a previously described Acadian USH1C
patient [5] and the heterozygous healthy carrier from the
Quebec population (Figure 1b). Moreover, we found evidence
for historical meiotic recombinations of both intragenic SNPs
and a closely flanking microsatellite marker (haplotypes 1 to
4 and 6 to 8, respectively).http://genomebiology.com/2007/8/4/R47 Genome Biology 2007,     Volume 8, Issue 4, Article R47       Ebermann et al. R47.3
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USH1 gebec and haplotype analysis of the USH1C founder mutation c.216G>A Figure 1
USH1 gene mutations in Quebec and haplotype analysis of the USH1C founder mutation c.216G>A. (a) Distribution and proportion of USH1 gene 
mutations in Quebec. Numbers designate patients, colors indicate different USH1 genes. Superscript symbols indicate different mutations that are listed 
beside the diagram. Note that c.216G>A is present all along the St Lawrence river, suggesting that it was present from the beginning of colonization by 
French settlers. In sum, USH1C mutations account for 60% of USH1 cases investigated in this study. In the case of patient 1881, no mutation could be 
identified in any of the known USH1 genes. See Additional data file 4 for the precise origin of each patient. (b) Genomic structure of the USH1C gene and 
haplotype bearing the c.216G>A mutation in different patients. Constitutive exons are given in black, alternatively spliced exons in grey. Mutations 
identified in this study are given above. Asterisks indicate novel mutations. Designations of intragenic SNPs and polymorphic microsatellite repeat markers 
are given below (SNPs in bold are referred to in Figure 2). The corresponding UCSC map positions are indicated below the scheme of the USH1C gene. 
'VNTR' designates the 45 bp variable number of tandem repeat polymorphism in intron 5, which is in complete linkage disequilibrium with the c.216G>A 
mutation. Presence of the 9VNTR(t,t) allele is indicated by '9'. Alleles of microsatellite markers are represented by numbers indicating different repeat 
lengths. Slashes indicate that marker alleles could not be assigned definitively to a haplotype. For biallelic SNPs, the respective nucleotide is given 
(according to the genomic USH1C sequence in 5'-3' orientation). Haplotype IDs and respective patients are given in the left column. Haplotypes associated 
with c.216G>A are in red. For patients who are compound heterozygous for c.216G>A and another mutation, only the c.216G>A-associated haplotype is 
shown. Recombination events are indicated by grey background. Acadian: for comparison of the c.216G>A-associated haplotype ('Acadian allele') with 
haplotypes in our sample, we have genotyped the family of a previously described patient with homozygosity for c.216G>A (see Additional data file 1a). As 
there is a recombination event in this patient for marker D11S1349, both alleles are shown. 1-4: haplotypes from patients 1172, 367, 554, and 1116 who 
are homozygous for c.216G>A. In the case of a recombination event, only the corresponding allele is shown. 5-7: c.216G>A-associated haplotypes from 
compound heterozygous patients. 8: c.216G>A-associated haplotype from healthy carrier (Q14).
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Figure 2 (see legend on next page)
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The insertion c.238-239insC has previously been found in
several USH1 cases from Europe, Asia, and North America
[11,15,18]. Despite the overall low prevalence of USH1C in
most populations, c.238-239insC has been found in 14% and
12.5% of USH1 patients in the UK and Germany, respectively,
which may be due to founder effects [15,18]. Haplotype anal-
ysis in our patients carrying c.238-239insC was in line with
haplotype data available from European patients with that
mutation (see Additional data file 2).
Using data from the HapMap project, the USH1C mutations
identified in our study could all be assigned to USH1C haplo-
types predicted to be present in the Central European popu-
lation (CEU), supporting the results of our analyses (Figure
2). Both c.216G>A and the novel p.R155X mutation origi-
nated on the most common USH1C  CEU haplotype. The
mutations c.238-239insC, c.496+1G>T and c.748_759+5del
probably occurred independently on the background of the
second most common CEU haplotype. While the haplotype
associated with the insertion in our patients is centromeri-
cally restricted because of different alleles for the marker
D11S1349, probably indicating an older mutation, the haplo-
type bearing the c.496+1G>T mutation is identical over the
whole range of analyzed markers (7.9 Mb) in both patients
with this mutation.
CDH23 mutations
Two patients were homozygous for the CDH23  mutation
IVS45-9G>A and showed the same haplotype as previously
reported for German patients with this mutation [19], sug-
gesting a common origin of this mutation (see Additional data
file 3). Another patient was compound heterozygous for
IVS45-9G>A and a novel nonsense mutation, c.2206C>T
(p.R736X). Thus, CDH23 mutations are responsible for 20%
of USH1 cases in our study (Figure 1a).
MYO7A and USH3A mutations
Only one patient in our study had mutations in MYO7A, the
most common USH1 gene in most other populations; this
patient was compound heterozygous for the previously
reported missense mutation c.1370C>T (p.A457V) [20], and
a novel nonsense mutation, c.2443C>T (p.Q815X). One of the
USH1 patients investigated here was homozygous for a novel
missense mutation in the USH3A gene, p.A123D (c.368C>A),
which is likely to be pathogenic as p.A123 is evolutionarily
conserved (data not shown) and the change was not present
in controls (100 French Canadians and 93 from mixed ethnic
groups). One patient did not show any pathogenic change in
any USH1 gene.
Discussion
F r e n c h  s e t t l e m e n t  i n  N o r t h  America started in 1608 and
occurred in mainly two regions: along the St Lawrence River
(the later Quebec) and in Acadia (today corresponding to New
Brunswick and Nova Scotia). The Acadians, many of whom
were deported to the United States in 1755, gave rise to the
later populations of Maritime Canada and to the Cajuns of the
southern US. Some Acadians escaped deportation and moved
to what is now Quebec. By the English conquest in 1759,
French immigration stopped. Linguistic and religious barri-
ers discouraged admixture with the mostly Protestant Eng-
lish-speaking new settlers. Highest birth rates occurred at
pioneer fronts, that is, rural regions opened to colonization,
which existed until the early 20th century. Quebec has been
considered a mosaic of layered founder effects, resulting from
the distinct settlers' gene pools of the respective pioneer
fronts. Despite modern mobility, secularization, urbanization
and immigration in the second half of the 20th century, his-
torical founder effects still have a strong impact on medical
genetics and public health in Quebec. As a result, some dis-
eases are found more frequently or exclusively in French
Canadians from Quebec than in other populations, or they
have special clinical or genetic features (for example, agenesis
of corpus callosum and peripheral neuropathy). Frequently, a
few founder mutations account for the vast number of cases
of a given phenotype [14].
The genetic conditions found in Quebec are generally not
found in Acadians, or they are due to different mutations (for
example, oculopharyngeal muscular dystrophy) [14]. In the
case of USH1, our results challenge this point of view: we have
shown that the USH1C  mutation c.216G>A, the 'Acadian
allele', is the main cause of USH1 in Quebec, accounting for
40% of USH1 disease alleles and being found all along the St
Lawrence River (Figure 1a). In Acadians, c.216G>A is respon-
sible for virtually all USH1 cases (only one out of 44 Acadian
USH1 cases has been shown not to be homozygous, but com-
pound heterozygous for c.216G>A and c.238-239insC [17]).
The 9VNTR(t,t) in intron 5 and the c.216G>A mutation are in
complete linkage disequilibrium and are almost exclusively
found in Acadians, raising the possibility of a recent origin of
c.216G>A in this population [17]. Our data now strongly sug-
gest that carriers of c.216G>A belong to the early founders of
Haplotype structure of the USH1C gene locus in Europeans Figure 2 (see previous page)
Haplotype structure of the USH1C gene locus in Europeans. (a) Structure of the USH1C gene with relative positions of mutations identified in this study 
and SNPs typed by the HapMap project [30]. Rate (D') of linkage disequilibrium (LD; visualized by haploview program) is represented by different colors 
(highest rate of LD in dark red and lower LD in light red/white). The marked block defines potential haplotypes between selected SNPs. Note that the 
orientation of the graphic is opposite to Figure 1b and that SNP alleles are given in reverse complement. (b) Potential haplotypes in the European 
population (CEU) for four selected SNPs that have been genotyped in our study. F: putative frequency of these haplotypes in CEU as determined in the 
HapMap project. The 'Acadian allele', c.216G>A, and p.R155X are both located on the most prevalent haplotype predicted to account for 50% of 
haplotypes. c.238-239insC, c.496+1G>T and c.748_759+5del are located on the second most common haplotype.R47.6 Genome Biology 2007,     Volume 8, Issue 4, Article R47       Ebermann et al. http://genomebiology.com/2007/8/4/R47
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both the Acadian and the Quebec population (Figure 1b). This
would explain its wide distribution all along the St Lawrence
River valley, following the direction of the historical coloniza-
tion movement (Figure 1a).
USH1C has so far been considered rare outside Acadia and
peoples descended from that region, accounting for 7% of
USH1 cases in a recent study on US and UK patients [11].
Roux et al. [21] have performed extensive mutation screening
in USH1 patients from France and found USH1C mutations in
only 6% of cases. Of note, c.216G>A was not detected; this
resembles the rhodopsin p.P23H mutation, which has been
found in 12% of Irish-American families with autosomal dom-
inant RP, but not in Europe [22]. Strikingly, USH1C muta-
tions account for 60% of USH1 in the patients investigated
here, followed by CDH23/USH1D (20%). MYO7A mutations
(USH1B), which are responsible for the main proportion of
USH1 cases in other populations, only play a minor role (one
patient). To date, only six USH1-causing mutations have been
identified in the USH1C  gene [5,8,15]. In our collective
derived from a founder population, however, we met unex-
pected allelic heterogeneity: five different USH1C mutations,
including three novel (p.R155X, c.496+1G>T, and
c.748_759+5del), were found. These novel changes, although
probably rare in most cases and likely to be of recent origin at
a given pioneer front in some, could clinically manifest
because of the high prevalence of c.216G>A. Although digenic
inheritance of type 1 has been described in USH1 [23], we did
not find this pattern of inheritance in our patients. Thus,
there is no indication that USH1C is involved in digenic Usher
syndrome, at least probably not in combination with the other
USH genes found to be mutated here.
We show that the Quebec population is the second population
in the world in which USH1C is the major genetic USH1 sub-
type, which is rare in all other populations studied to date.
USH1 is a severely disabling disorder, causing major commu-
nication handicap due to congenital deafness and progressive
retinal degeneration resulting in legal blindness in most
cases. There are no official numbers describing the incidence
of Usher syndrome in Quebec. However, the carrier rate of
approximately 0.44% solely for the USH1C  mutation
c.216G>A in the Quebec population suggests an incidence of
Usher syndrome type 1C of 0.5 per 100,000 (assuming ran-
dom mating and complete penetrance), based on c.216G>A
alone. Assuming a minimum incidence of 1 per 1,000 for chil-
dren with congenital profound hearing impairment [24],
0.5% of these children may develop additional retinitis pig-
mentosa due to homozygosity for the USH1C  mutation
c.216G>A. Since 60% of USH1 cases in our study are due to
other mutations (20% of which also affect the USH1C gene),
and because of local founder effects (also for other USH1 sub-
types such as USH1D), the incidence for USH1 may (region-
ally) be even higher.
While routine testing for USH1 gene mutations is hampered
by the number and size of the genes involved in most popula-
tions, our data should facilitate molecular diagnosis of deaf-
ness and Usher syndrome in Quebec (>60% of cases have a
mutation in USH1C and >90% of cases can be explained by
ten mutations). Knowledge that a mutation in a profoundly
deaf child will result in severe visual impairment in later life
is important for rehabilitative strategies: parents may be
more likely to choose cochlear implantation for their child
rather than visual modes of communication such as sign
language.
Our findings suggest that the USH1C mutation c.216G>A is
one of only a handful of common single USH1 mutations,
along with founder mutations in USH3A in the Finnish and
the Ashkenazi Jewish population and a PCDH15/USH1F
founder allele in Ashkenazi Jews [12,25,26]; moreover, it is
predominant in two populations. The recent development of
a mouse model carrying the c.216G>A mutation in USH1C is
an important step in the development of a specific therapeutic
approach for the treatment or amelioration of this devastat-
ing condition in affected individuals with the c.216G>A muta-
tion [27].
Conclusion
Our study sheds new light on the colonization history of two
North American regions and their populations, French Cana-
dians from Quebec and Acadians. Moreover, the finding of a
wide-spread founder mutation for an otherwise rare genetic
subtype of deafblindness is of great importance to the medical
community as this knowledge should strongly influence diag-
nostic and therapeutic management of congenitally deaf chil-
dren in Quebec.
Materials and methods
Patients
French Canadian subjects from Quebec with USH1 were iden-
tified through the McGill Ocular Genetics Laboratory, Mon-
treal Children's Hospital Research Institute, McGill
University Health Center, Montreal, Quebec, Canada (see
Additional data file 4 for precise origin of each patient). The
study was performed according to the Declaration of Helsinki
and approved by the institutional review boards of both insti-
tutions involved (ethics committees of McGill University and
the University Hospital of Cologne). Written informed con-
sent was obtained from all participants. All patients met the
diagnostic criteria for USH1.
The healthy control individuals (all had negative family his-
tory for Usher syndrome) came from all regions of Quebec.
Detection of mutations and haplotype analyses
Genomic DNA was extracted from venous EDTA blood sam-
ples. To identify founder mutations in USH1 patients fromhttp://genomebiology.com/2007/8/4/R47 Genome Biology 2007,     Volume 8, Issue 4, Article R47       Ebermann et al. R47.7
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Quebec, we followed a combination of different strategies. We
performed genotyping of polymorphic microsatellite markers
closely flanking the seven USH1 loci in parallel with a muta-
tion screening strategy. In the  c a s e  o f  h o m o z y g o s i t y  f o r
marker alleles of a specific USH1 locus, the coding region of
the corresponding gene was sequenced. Where these
approaches did not lead to the identification of the genetic
subtype, we sequenced the entire coding regions of all USH1
genes, in the order of mutation prevalences in other popula-
tions:  MYO7A  (USH1B),  CDH23  (USH1D),  USH1C, and
PCDH15 (USH1F). Once a mutation was identified, all other
patients were screened for this change. As USH1C mutations
have so far only been reported in exons 1, 2, 3, 5 and 6, these
exons were sequenced first. The small genes SANS (USH1G)
and USH3A (which was screened because it has previously
been reported to be causative in some USH1 patients) were
also analyzed by direct sequencing in parallel with
microsatellites.
PCR was carried out following standard protocols and using
gene-specific primers that amplify the coding exons and adja-
cent intronic sequences. For amplification of locus-specific
polymorphic microsatellite repeat markers, we used fluores-
cent dye-labeled primers. For the amplification of several
markers, we applied the tailed primer method as described
previously [28] (primers and protocols available on request).
Purified PCR fragments were sequenced using Big Dye Ter-
minator Cycle sequencing (Applied Biosystems, Foster City,
CA, USA) and analyzed on an ABI-377 DNA sequencer by cap-
illary electrophoresis. Microsatellite markers were also ana-
lyzed on an ABI-377 DNA sequencer and genotypes were
determined by GeneScan software (Applied Biosystems).
Data provided by the Genome Database [29] were used as ref-
erences for allele sizes. SNPs were genotyped by either
restriction enzyme digest of corresponding PCR fragments or
by direct sequencing. Samples were genotyped for the pres-
ence of the 9VNTR(t,t) allele of the VNTR polymorphism in
intron 5 of the USH1C  gene as described previously [17].
Screening for the mutations detected in this study in other
p a t i e n t s  a n d  i n  n o r m a l  c o n t r o l s  w a s ,  i n  p a r t ,  p o s s i b l e  b y
restriction enzyme digest (DraIII for c.216G>A (USH1C),
Bsp119I for p.R155X (USH1C),  Esp3I for c.496+1G>T
(USH1C), and NheI for p.Q815X (MYO7A)). Screening for the
USH1C insertion c.238-239insC in exon 3 was performed by
using fluorescent dye-labeled primers for amplification of
exon 3 and subsequent analysis of fragment length on the
ABI-377 DNA sequencer. DNA mutation numbering of iden-
tified mutations was given based on cDNA sequences of Gen-
Bank entries given below, with +1 corresponding to the A of
the ATG translation initiation codon (codon 1) in the respec-
tive reference sequence.
Accession numbers
USH1C  mRNA, isoform b3 (GenBank:NM_153676.2);
CDH23  mRNA (GenBank:AF312024.1);  MYO7A  mRNA
(GenBank:NM_000260.2);  USH3A  mRNA
(GenBank:AF482697.1).
Additional data files
The following additional data are available with the online
version of this paper. Additional data file 1 is a figure showing
the USH1C genotypes identified in this study. (a) The family
of an Acadian USH1 patient that has previously been shown
to be homozygous for the Acadian founder mutation,
c.216G>A [5], was available for haplotype analysis. USH1C
haplotypes are represented by vertical colored bars
(c.216G>A-associated haplotype in red). See Figure 1b and
Figure 2 for detailed haplotypes. (b)  Two brothers with
homozygosity for c.216G>A, which was also found in patients
367, 1116, and 1172. (c)  Compound heterozygosity for
c.216G>A and c.238-239insC in two brothers. (d) Compound
heterozygosity for c.216G>A and the novel nonsense muta-
tion p.R155X (patient 475). (e) Compound heterozygosity for
c.216G>A and a novel splice site mutation, c.496+1G>T,
which affects the invariant donor splice site of exon 5
(patients 848 and 1115). (f)  Compound heterozygosity for
c.238-239insC and the novel 17 bp deletion 748_759+5del,
which removes 12 exonic and five intronic base-pairs, includ-
ing the donor splice site of exon 9 (patient 465). Additional
data file 2 is a figure that displays the haplotypes associated
with  USH1C  mutations c.238-239insC, p.R155X,
c.748_759+5del, and c.496+1G>T. SNPs in bold are referred
to in Figure 2. '∅' indicates absence of the 9VNTR(t,t) allele.
European: haplotype associated with c.238-239insC in Euro-
pean patients as published by Zwaenepoel et al. [15]. 1-2: hap-
lotype associated with c.238-239insC in our patients
(compound heterozygosity for c.748_759+5del and
c.216G>A, respectively). Common haplotypes in Quebec and
European USH1 patients carrying the c.238-239insC muta-
tion suggest that the mutation probably has recently been
locally 'imported' by other ethnic communities after comple-
tion of settlement. Note different alleles for D11S1349 on the
chromosome carrying c.238-239insC in patients 465 and
505, respectively. 3: haplotype associated with c.496+1G>T. 4
and 5: Haplotypes associated with novel mutations
c.748_759+5del and p.R155X, respectively. Additional data
file 3 is a figure that displays the haplotypes associated with
CDH23 mutation IVS45-9G>A. Homozygosity for the CDH23
mutation IVS45-9G>A was found in patients 303 and 1235,
while patient 860 was compound heterozygous for IVS45-
9G>A and the novel nonsense mutation p.R736X. SNP alleles
are given according to the genomic CDH23 sequence in 5'-3'
orientation. The haplotype associated with IVS45-9G>A in
Quebec patients matches with the CDH23 haplotype of two
German families that we have investigated previously [19]. As
in the case of c.238-239insC, this could be due to settlement
of ethnic groups other than French Canadians. Note recombi-
nation event for marker D10S1759 in patient 1235. N.d. = not
determined. Additional data file 4 consists of a table and a
map figure illustrating the precise origins of patientsR47.8 Genome Biology 2007,     Volume 8, Issue 4, Article R47       Ebermann et al. http://genomebiology.com/2007/8/4/R47
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investigated in this study. The map illustrates the location of
the places given in the table (cities associated with patients
carrying c.216G>A in red). See also Figure 1a. Additional data
file 5 consists of figures illustrating the haplotypes of patients
with  USH1C  and  CDH23/USH1D  mutations. Fragment
length analysis is shown for microsatellite markers (GeneS-
can, Applied Biosystems), electropherograms for SNPs, and
agarose gel electrophoresis for the VNTR in intron 5 of the
USH1C gene. Additional data file 6 comprises figures that
show all mutations that have been identified in USH1 patients
that have been investigated in this study (electrophero-
grams), and figures for genotyping of healthy French Cana-
dian control individuals for these mutations (by direct
sequencing, restriction enzyme digest, and fragment length
analysis). Additional data file 7 contains figures that illustrate
results of mutation screening in patient 1881 in the following
genes: MYO7A (USH1B) and USH1C (no mutations found).
Additional data file 8 contains figures that illustrate results of
mutation screening in patient 1881 in the CDH23  gene
(USH1D) (no mutations found). Additional data file 9 con-
tains figures that illustrate results of mutation screening in
patient 1881 in the following genes: PCDH15 (USH1F), SANS
(USH1G) and USH3A (no mutations found).
Additional data file 1 USH1C genotypes identified in this study USH1C genotypes identified in this study. (a) The family of an Aca- dian USH1 patient that has previously been shown to be  homozygous for the Acadian founder mutation, c.216G>A [5], was  available for haplotype analysis. USH1C haplotypes are repre- sented by vertical colored bars (c.216G>A-associated haplotype in  red). See Figure 1b and Figure 2 for detailed haplotypes. (b) Two  brothers with homozygosity for c.216G>A, which was also found in  patients 367, 1116, and 1172. (c) Compound heterozygosity for  c.216G>A and c.238-239insC in two brothers. (d) Compound het- erozygosity for c.216G>A and the novel nonsense mutation  p.R155X (patient 475). (e) Compound heterozygosity for c.216G>A  and a novel splice site mutation, c.496+1G>T, which affects the  invariant donor splice site of exon 5 (patients 848 and 1115). (f)  Compound heterozygosity for c.238-239insC and the novel 17 bp  deletion 748_759+5del, which removes 12 exonic and five intronic  base-pairs, including the donor splice site of exon 9 (patient 465). Click here for file Additional data file 2 Haplotypes associated with USH1C mutations c.238-239insC,  p.R155X, c.748_759+5del, and c.496+1G>T SNPs in bold are referred to in Figure 2. '∅' indicates absence of the  9VNTR(t,t) allele. European: haplotype associated with c.238- 239insC in European patients as published by Zwaenepoel et al.  [15]. 1-2: haplotype associated with c.238-239insC in our patients  (compound heterozygosity for c.748_759+5del and c.216G>A,  respectively). Common haplotypes in Quebec and European USH1  patients carrying the c.238-239insC mutation suggest that the  mutation probably has recently been locally 'imported' by other  ethnic communities after completion of settlement. Note different  alleles for D11S1349 on the chromosome carrying c.238-239insC in  patients 465 and 505, respectively. 3: haplotype associated with  c.496+1G>T. 4 and 5: Haplotypes associated with novel mutations  c.748_759+5del and p.R155X, respectively. Click here for file Additional data file 3 Haplotypes associated with CDH23 mutation IVS45-9G>A Homozygosity for the CDH23 mutation IVS45-9G>A was found in  patients 303 and 1235, while patient 860 was compound hetero- zygous for IVS45-9G>A and the novel nonsense mutation p.R736X.  SNP alleles are given according to the genomic CDH23 sequence in  5'-3' orientation. The haplotype associated with IVS45-9G>A in  Quebec patients matches with the CDH23 haplotype of two Ger- man families that we have investigated previously [19]. As in the  case of c.238-239insC, this could be due to settlement of ethnic  groups other than French Canadians. Note recombination event for  marker D10S1759 in patient 1235. N.d. = not determined. Click here for file Additional data file 4 Precise origins of patients investigated in this study The map illustrates the location of the places given in the table (cit- ies associated with patients carrying c.216G>A in red). See also Fig- ure 1a. Click here for file Additional data file 5 Haplotypes of patients with USH1C and CDH23/USH1D mutations Fragment length analysis is shown for microsatellite markers  (GeneScan, Applied Biosystems), electropherograms for SNPs, and  agarose gel electrophoresis for the VNTR in intron 5 of the USH1C  gene. Click here for file Additional data file 6 All mutations that have been identified in USH1 patients that have  been investigated in this study and genotyping of healthy French  Canadian control individuals for these mutations All mutations that have been identified in USH1 patients that have  been investigated in this study (electropherograms), and figures for  genotyping of healthy French Canadian control individuals for  these mutations (by direct sequencing, restriction enzyme digest,  and fragment length analysis). Click here for file Additional data file 7 Results of mutation screening in patient 1881 in the genes MYO7A  (USH1B) and USH1C (no mutations found) Results of mutation screening in patient 1881 in the genes MYO7A  (USH1B) and USH1C (no mutations found). Click here for file Additional data file 8 Results of mutation screening in patient 1881 in the CDH23 gene  (USH1D) (no mutations found) Results of mutation screening in patient 1881 in the CDH23 gene  (USH1D) (no mutations found). Click here for file Additional data file 9 Results of mutation screening in patient 1881 in the genes PCDH15  (USH1F), SANS (USH1G) and USH3A (no mutations found) Results of mutation screening in patient 1881 in the genes PCDH15  (USH1F), SANS (USH1G) and USH3A (no mutations found). Click here for file
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